Chronic Obstructive Pulmonary Disease (COPD) – Market Access and Reimbursement Insights Report – 2025

Chronic Obstructive Pulmonary Disease (COPD) Market Access and Reimbursement Insights

Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. As the third leading cause of death worldwide, its prevalence and fatality rates are projected to rise in the coming decades. The disease is characterized by chronic inflammation that causes structural alterations and constriction in the smaller air passages. This inflammatory process also drives lung tissue damage, resulting in the detachment of alveoli from smaller airways and a decrease in lung elasticity, which ultimately reduces the airways’ ability to remain open during exhalation. To assess the extent of airflow restriction, spirometry serves as the most accessible and dependable measure of lung function, with diagnosis confirmed by a post-bronchodilator FEV1/FVC ratio of less than 0.70. The clinical impact of COPD on an individual is determined not only by the degree of airflow limitation but also by the severity of associated symptoms and the frequency of exacerbations. Because an imperfect correlation exists between the degree of airflow limitation and patient symptoms, modern staging acts as a practical framework that combines spirometric grading with symptom burden and exacerbation risk to guide the initial management plan.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Chronic Obstructive Pulmonary Disease (COPD) – Market Access and Reimbursement Insights Report – 2025